EYPT Stock Forecast: EyePoint, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for EyePoint, Inc. is $4. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 21 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores EyePoint, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (81): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (3): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
EYPT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on EYPT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 2 moved their price target up and 8 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Nov 2026 | Stifel | Maintains | Buy | $6.00 → $5.00 |
| 20 Oct 2026 | Guggenheim | Downgrade | Neutral | — |
| 20 Oct 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 20 Oct 2026 | JP Morgan | Downgrade | Underweight | — |
| 20 Oct 2026 | Laidlaw & Co. | Downgrade | Hold | — |
| 20 Oct 2026 | RBC Capital | Maintains | Sector Perform | $5.00 → $1.00 |
| 2 Sept 2026 | TD Cowen | Downgrade | Hold | $20 → $4.00 |
| 18 Aug 2026 | Chardan Capital | Downgrade | Neutral | $65 → $5.00 |
| 18 Aug 2026 | Citigroup | Maintains | Buy | $35 → $17 |
| 18 Aug 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 18 Aug 2026 | RBC Capital | Downgrade | Sector Perform | $37 → $5.00 |
| 17 Aug 2026 | Chardan Capital | Maintains | Buy | $65 |
| 17 Aug 2026 | Jefferies | Maintains | Buy | $30 → $8.00 |
| 17 Aug 2026 | JP Morgan | Downgrade | Neutral | — |
| 7 Aug 2026 | Chardan Capital | Maintains | Buy | $65 |
| 6 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | $47 → $55 |
| 6 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $30 → $27 |
| 16 July 2026 | Stifel | Initiates | Buy | $40 |
| 8 July 2026 | Cantor Fitzgerald | Assumes | Overweight | $47 |
| 1 July 2026 | Chardan Capital | Maintains | Buy | $29 → $65 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for EYPT.
This page is one stock. Monday covers all of them.
EYPT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
EYPT vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, EyePoint, Inc. returned −98.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
EYPT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 10.3×
- Price / book
- 0.2×
- EV / EBITDA
- —
Cheaper than 12% of US stocks
Cheaper than 94% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 100.0%
- Operating margin
- —
- Net margin
- —
Higher than 99% of US stocks
- Return on equity
- −221.9%
- Return on assets
- −105.3%
- Dividend yield
- —
Higher than 7% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
EyePoint, Inc. has a market value of $26.2M.
Revenue in the twelve months to 30 June 2026: $2.8M. The latest quarter shrank 90.5% year on year.
Net income over the same four quarters: −$306.6M, a −10994.7% net margin.
Diluted earnings per share, trailing twelve months: −$3.74.
Free cash flow in the twelve months to 30 June 2026: −$271.3M.
EyePoint, Inc. employs 214 people — $13K of revenue per employee.
Data provided by Twelve Data
EYPT and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at EYPT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own EyePoint, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about EYPT
What is the EYPT stock price forecast for 2026-2027?
The median 12-month analyst price target for EyePoint, Inc. is $4, with estimates ranging from $0.5 to $31. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is EYPT stock a buy right now?
Of the 13 analysts covering EyePoint, Inc., 2 rate it a Buy, 10 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks EyePoint, Inc. 21 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank EYPT?
As at 21 Nov 2026, EyePoint, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (81 of 100).
Will EYPT stock go up?
No one can know that. What the data says: the median 12-month target from 13 analysts is $4, and Ticker Nerd's factor model ranks EyePoint, Inc. 21 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the EYPT stock forecast for 2030?
No analyst covering EyePoint, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EYPT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.5 to $31 over the next 12 months.
How has EYPT stock performed over the past year?
EyePoint, Inc. returned -98.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does EyePoint, Inc. do?
EyePoint, Inc. Common Stock represents equity in EyePoint, Inc., a biopharmaceutical company focused on developing and commercializing therapies for serious retinal diseases. The company’s current portfolio centers on ophthalmology products and sustained-release drug delivery technologies designed to treat eye disorders and improve the management of retinal conditions.
About EyePoint, Inc.
EyePoint, Inc. Common Stock represents equity in EyePoint, Inc., a biopharmaceutical company focused on developing and commercializing therapies for serious retinal diseases. The company’s current portfolio centers on ophthalmology products and sustained-release drug delivery technologies designed to treat eye disorders and improve the management of retinal conditions. Its marketed and development-stage programs address areas such as retinal vascular disease, diabetic macular edema, and other eye diseases, using proprietary platforms that support localized, long-acting treatment delivery. EyePoint, Inc. serves the specialized eye-care market, working with healthcare providers and the broader ophthalmic industry through products and pipeline assets that target chronic retinal conditions. Headquartered in Watertown, Massachusetts, the company is positioned within the life sciences sector as a developer of therapies and drug-delivery systems for ophthalmic use.
CEO Dr. Jay S. Duker M.D. · 214 employees · United States · https://eyepoint.bio